In a significant policy shift, President Trump has signed an executive order reclassifying marijuana as a Schedule III drug, aiming to facilitate medical research and ease restrictions on cannabis. This move is expected to impact both the cannabis industry and research initiatives, sparking financial hopes for businesses and advocates. The reclassification may also lead to increased access to cannabis and CBD, emphasizing their medical benefits. While some lawmakers criticize the decision, others celebrate it as a breakthrough that could create thousands of jobs and provide tax relief for cannabis businesses. The order is viewed as a direct response to lobbying from the cannabis industry and reflects an evolving attitude towards marijuana at the federal level.